Lisa McClain's VRTX trades
- The latest VRTX trade was a sale on Jun 11, 2025, when VRTX closed at $452.44. It closed at $533.35 on Nov 3, 2026 (+18%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Lisa McClain reported 3 VRTX transactions in 1 filing with the House Clerk for 2025–2026: 1 purchase and 2 sales of Vertex Pharmaceuticals Incorporated, with trade dates from Dec 11, 2024 to Jun 11, 2025. The median gap between trade date and filing date is 64 days, and 3 trades were reported more than 45 days after it happened.
- 3
- 1 / 2
- $3K – $45K
- 2025-08-13
VRTX transactions reported by Lisa McClain
| Type | Owner | ||||
|---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated - Common Stock VRTX | Sale | Spouse | $1,001 - $15,000 | 2025-08-13 #20030891 | |
Vertex Pharmaceuticals Incorporated - Common Stock VRTX | Sale | Spouse | $1,001 - $15,000 | 2025-08-13 #20030891 | |
Vertex Pharmaceuticals Incorporated - Common Stock VRTX | Purchase | Spouse | $1,001 - $15,000 | 2025-08-13 #20030891 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 0
- 31–45 days
- 0
- Over 45 days
- 3
- Median / longest
- 64d / 245d
Source documents
1 House Clerk periodic transaction report, newest first. Each link opens the official filing.
- #20030891Filed 2025-08-13 · 3 rows
What Lisa McClain's VRTX filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Vertex Pharmaceuticals Incorporated financials and filings
Audited SEC figures, what moves VRTX, and primary sources.
Compare LLY vs VRTX side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchOther members of Congress who reported VRTX
More tickers reported by Lisa McClain
Go deeper
Lisa McClain and VRTX: questions
Did Lisa McClain buy or sell VRTX?
House Clerk filings for 2025 and 2026 show 1 purchase and 2 sales of Vertex Pharmaceuticals Incorporated (VRTX) reported by Lisa McClain, between 2024-12-11 and 2025-06-11. Reported owner: Spouse.
How much VRTX did Lisa McClain trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $3K – $45K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last VRTX filing by Lisa McClain?
The most recent filing that includes a VRTX trade was filed on 2025-08-13. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Vertex Pharmaceuticals Incorporated. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Lisa McClain VRTX disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included